Saturday 17 October 2026
Export AAPG’s income statement to Excel — free account
Ascentage Pharma Group International - Unsponsored ADR
AAPG Healthcare Biotechnology
Ascentage Pharma Group International - Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $82.1 million, down 38.9% from fiscal 2024.
15.37
0.68
+4.63%
Follow AAPG
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 |
Altman Z-Score |
— | — | — | 0.81 |
Altman Z″-Score (non-manufacturers) |
— | (8.14) | (7.14) | (5.09) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | (0.64) | 0.58 |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | 0.21 |
EV/FCF |
0.00 | 0.00 | 0.00 | 0.20 |
Quick Ratio |
— | 1.33 | 1.15 | 1.66 |
Current Ratio |
— | 1.44 | 1.26 | 1.79 |
Net Debt/EBITDA |
0.00 | (0.93) | (1.64) | 0.44 |
Debt/Assets |
0.00% | 71.81% | 63.74% | 49.95% |
Debt/Equity |
— | 25.42 | 6.09 | 1.48 |
Asset Turnover |
0.00 | 0.18 | 0.38 | 0.18 |
Operating CF/Net income |
0.00 | 0.78 | 0.27 | 0.94 |
Capex/Depreciation |
— | (0.70) | (0.30) | (0.36) |
Interest Coverage |
— | (8.72) | (5.13) | (21.87) |
| 0.00% | 0.00% | (234.96%) | (155.65%) | |
| 0.00% | (74.04%) | (15.81%) | (38.41%) | |
ROIC |
0.00% | (67.80%) | (30.31%) | (87.57%) |
Return on Tangible Assets |
0.00% | (70.35%) | (35.04%) | (59.69%) |
Average Days of Receivables |
0.00 | 239.89 | 30.94 | 160.81 |
Research and Development Expense of Revenue |
0.00% | 318.48% | 96.59% | 198.12% |
Selling, General and Administrative Expense of Revenue |
0.00% | 169.59% | 39.07% | 104.49% |
Intangible Assets out of Total Assets |
0.00 | 0.04 | 0.04 | 0.02 |
Share Based Compensation of Revenue |
0.00% | 14.19% | 2.13% | 3.64% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.47 | 0.43 | 1.78 | 0.92 |
Operating CF per Share |
0.00 | (1.42) | (0.20) | (1.89) |
Capex per Share |
0.00 | (0.11) | (0.04) | (0.04) |
Free Cash Flow per Share |
0.00 | (1.53) | (0.25) | (1.93) |
Cash per Share |
0.00 | 2.13 | 2.29 | 3.97 |
Shareholders Equity per Share |
0.00 | 0.14 | 0.50 | 2.14 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.14 | 0.50 | 2.14 |
Free Cash Flow |
— | (107.73) | (18.58) | (171.84) |
Working Capital |
— | 56.42 | 42.13 | 186.01 |
Capital Expenditures |
— | (7.82) | (3.33) | (3.94) |
Net Current Asset Value |
— | (149.38) | (119.12) | 45.02 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.26 | 0.02 | 0.05 |
| Other line items | ||||
Depreciation/Fixed assets |
— | 0.09 | 0.10 | 0.10 |
Cash ROIC |
— | (26.45%) | (4.23%) | (20.78%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 8.54 | 3.45 |
Accounts Payable Turnover |
— | 0.00 | 0.35 | 0.50 |
Inventory Turnover |
— | 0.00 | 2.55 | 2.80 |
Average Days of Payables |
— | 865.74 | 1,154.28 | 796.14 |
Days of Inventory on Hand |
— | 193.23 | 82.82 | 213.43 |
Average Receivables |
— | — | 15.73 | 23.78 |
Average Payables |
— | — | 11.28 | 13.93 |
Average Inventory |
— | — | 1.56 | 2.50 |
Average Assets |
— | 172.03 | 351.35 | 462.71 |
Average Common Equity |
— | — | 23.64 | 114.17 |
Columns are period end dates